Carlos Gustavo De Moraes1, Jayter Silva Paula2, Dana M Blumberg3, George A Cioffi3, Lama A Al-Aswad3, Christopher A Girkin4, Robert N Weinreb5, Linda M Zangwill5, Robert Ritch6, Remo Susanna7, Donald C Hood8, Jeffrey M Liebmann3. 1. Bernard and Shirlee Brown Glaucoma Research Laboratory, Edward S. Harkness Eye Institute, Department of Ophthalmology, Columbia University Medical Center, New York, NY, USA; Department of Ophthalmology, University of Sao Paulo School of Medicine, Sao Paulo, SP, Brazil. Electronic address: cvd2109@cumc.columbia.edu. 2. Department of Ophthalmology, Otorhinolaryngology and Head Neck Surgery, Ribeirao Preto Medical School - University of Sao Paulo, Ribeirao Preto, SP, Brazil. 3. Bernard and Shirlee Brown Glaucoma Research Laboratory, Edward S. Harkness Eye Institute, Department of Ophthalmology, Columbia University Medical Center, New York, NY, USA. 4. Department of Ophthalmology, University of Alabama-Birmingham, Birmingham, AL, USA. 5. Hamilton Glaucoma Center, Viterbi Family Department of Ophthalmology, and Shiley Eye Institute, University of California-San Diego, San Diego, CA, USA. 6. Einhorn Clinical Research Center, Department of Ophthalmology, New York Eye and Ear Infirmary of Mount Sinai, New York. 7. Department of Ophthalmology, University of Sao Paulo School of Medicine, Sao Paulo, SP, Brazil. 8. Department of Psychology, Columbia University, New York, NY, USA.
Abstract
PURPOSE: To describe the development of a new algorithm for detecting changes in 10-2 visual field (VF) tests using event-based analysis and to test its validity in a second, independent glaucoma cohort. DESIGN: Prospective cohort study. METHODS: Patients with established open-angle glaucoma from the Macular Assessment and Progression Study (MAPS, development cohort, n=151), and the African Descent and Glaucoma Evaluation Study (ADAGES, validation cohort, n=52) were evaluated. The 10-2 VF results from MAPS were obtained during four test-retest sessions within a four-month period. For the validation analysis, 10-2 VF results from ADAGES performed on at least five visits were used. The event-based pointwise changes on 10-2 tests in the validation cohort were determined using two progression criteria: at least three progressing VF locations on two or three consecutive tests ("possible" or "likely" progression). Linear mixed-effects models were used to evaluate VF progression. RESULTS: In the validation cohort, the mean (SD) follow-up time was 2.3 (0.7) years. The number of eyes experiencing 10-2 VF progression based on "possible" and "likely" progression was 36 (54.5%) and 11 (16.6%), respectively. Eyes experiencing "possible" progression had MD changes [-0.60 dB/year (95% CI: -0.93 to -0.28)] faster than those not meeting this criterion (P<0.001), whereas for those with "likely" progression the difference was -0.91 dB/year (95% CI: -1.26 to -0.56, P<0.001). CONCLUSIONS: A new event-based progression algorithm using the 10-2 VF can identify eyes experiencing more rapid MD progression and may be used as a tool to assess progressive macular functional changes in glaucoma.
PURPOSE: To describe the development of a new algorithm for detecting changes in 10-2 visual field (VF) tests using event-based analysis and to test its validity in a second, independent glaucoma cohort. DESIGN: Prospective cohort study. METHODS:Patients with established open-angle glaucoma from the Macular Assessment and Progression Study (MAPS, development cohort, n=151), and the African Descent and Glaucoma Evaluation Study (ADAGES, validation cohort, n=52) were evaluated. The 10-2 VF results from MAPS were obtained during four test-retest sessions within a four-month period. For the validation analysis, 10-2 VF results from ADAGES performed on at least five visits were used. The event-based pointwise changes on 10-2 tests in the validation cohort were determined using two progression criteria: at least three progressing VF locations on two or three consecutive tests ("possible" or "likely" progression). Linear mixed-effects models were used to evaluate VF progression. RESULTS: In the validation cohort, the mean (SD) follow-up time was 2.3 (0.7) years. The number of eyes experiencing 10-2 VF progression based on "possible" and "likely" progression was 36 (54.5%) and 11 (16.6%), respectively. Eyes experiencing "possible" progression had MD changes [-0.60 dB/year (95% CI: -0.93 to -0.28)] faster than those not meeting this criterion (P<0.001), whereas for those with "likely" progression the difference was -0.91 dB/year (95% CI: -1.26 to -0.56, P<0.001). CONCLUSIONS: A new event-based progression algorithm using the 10-2 VF can identify eyes experiencing more rapid MD progression and may be used as a tool to assess progressive macular functional changes in glaucoma.
Authors: Donald C Hood; Sol La Bruna; Emmanouil Tsamis; Ari Leshno; Bruna Melchior; Jennifer Grossman; Jeffrey M Liebmann; Carlos Gustavo De Moraes Journal: Ophthalmol Glaucoma Date: 2022-03-28
Authors: Takashi Nishida; Sasan Moghimi; Huiyuan Hou; James A Proudfoot; Aimee C Chang; Ryan Caezar C David; Alireza Kamalipour; Nevin El-Nimri; Jasmin Rezapour; Christopher Bowd; Linda M Zangwill; Robert N Weinreb Journal: Br J Ophthalmol Date: 2021-12-21 Impact factor: 5.908
Authors: Ryan Caezar C David; Sasan Moghimi; Jiun L Do; Huiyuan Hou; James Proudfoot; Linda M Zangwill; Alireza Kamalipour; Takashi Nishida; Carlos Gustavo De Moraes; Christopher A Girkin; Jeffrey M Liebmann; Robert N Weinreb Journal: Am J Ophthalmol Date: 2021-06-06 Impact factor: 5.488